Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine from Eli Lilly, as the Danish drugmaker tries to seize market share among consumers paying cash for blockbuster GLP-1 therapies. Novo will sell the highest doses of its Wegovy pill, cleared last week, at…
Eli Lilly, Novo Nordisk race to lock in India obesity drug market We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
When HCA Healthcare, one of the largest hospital systems in the U.S., recently told employees it would stop covering blockbuster obesity drugs Zepbound and Wegovy next year, it pointed them to an alternative way to get the treatments: Buy them themselves. In a notice viewed by STAT, HCA said use of the GLP-1 weight loss…
Retatrutide Impresses in TRIUMPH-4 With Major Weight Loss & Pain Relief: A Strong Contender Beyond Tirzepatide We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide, showing average weight losses of up to 28.7% in its first phase 3 readout. Top-line results from the TRIUMPH-4 trial, carried out in patients overweight or with obesity and knee osteoarthritis, raise expectations for…
Drugmaker Cipla on Wednesday said it has launched a medication for managing obesity and type-2 diabetes mellitus. The company has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for obesity and type-2 diabetes mellitus, two of the country’s most pressing health challenges, the Mumbai-based drugmaker said in a regulatory filing. The company has the rights to…
Telehealth company Hims & Hers has launched its direct-to-consumer weight-loss therapy channel in the UK, offering GLP-1 agonists like Novo Nordisk’s Wegovy at a starting price of £149 per month. The move also marks the launch in the UK of the Hers part of the Hims & Hers business, which until now has focused mainly…
Eli Lilly Jaypirca met its primary endpoint in head-to-head Phase 3 study versus Imbruvica We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
CDSCO Panel Seeks Protocol Revisions in Levim Lifetech’s Teriparatide Biosimilar Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
A real-world study exploring the long-term effects of Eli Lilly’s weight-loss therapy tirzepatide in primary care settings has started in the UK. The five-year SURMOUNT-REAL UK trial, part of a collaboration signed last year between Lilly and the UK government, will chart the effects of tirzepatide on weight loss, diabetes prevention, and the prevention of…